Version 1
: Received: 30 September 2021 / Approved: 1 October 2021 / Online: 1 October 2021 (11:16:39 CEST)
How to cite:
Iacobas, S.; Iacobas, D. A. Personalized 1-2-3-Gene(s) Tickets to Cancer-Free Prostate. Preprints2021, 2021100003. https://doi.org/10.20944/preprints202110.0003.v1
Iacobas, S.; Iacobas, D. A. Personalized 1-2-3-Gene(s) Tickets to Cancer-Free Prostate. Preprints 2021, 2021100003. https://doi.org/10.20944/preprints202110.0003.v1
Iacobas, S.; Iacobas, D. A. Personalized 1-2-3-Gene(s) Tickets to Cancer-Free Prostate. Preprints2021, 2021100003. https://doi.org/10.20944/preprints202110.0003.v1
APA Style
Iacobas, S., & Iacobas, D. A. (2021). Personalized 1-2-3-Gene(s) Tickets to Cancer-Free Prostate. Preprints. https://doi.org/10.20944/preprints202110.0003.v1
Chicago/Turabian Style
Iacobas, S. and Dumitru A. Iacobas. 2021 "Personalized 1-2-3-Gene(s) Tickets to Cancer-Free Prostate" Preprints. https://doi.org/10.20944/preprints202110.0003.v1
Abstract
Many years and $$$ spent for research did not yet produced a universally effective gene therapy of prostate cancer (PCa). Our studies indicated that not only each human, but even each cancer nodule in the same tumor has unique and dynamic gene expression profile, control and coordination. The tumor heterogeneity of the transcriptome topology is a strong argument in favor of personalized gene therapies, tailored on patients’ primary tumor unique characteristics. Here, we propose a bioinformatics procedure by which to identify the Gene Master Regulators (GMR) of cancer cells from transcriptomic data and predict consequences of their experimental manipulation. The procedure, based on our Genomic Fabric Paradigm (GFP), can determine the most important gene in each cancer nodule whose controlled alteration would selectively kill the cancer cells. In this report, the method is applied to our microarray data on two men PCs (each with three distinct cancer nodules) and two standard human PCa cell lines (DU145 and LNCaP). We expect the industry to produce ready-to-use CRISPR constructs for all genes allowing the clinical oncologist to prescribe the adequate personalized CRISPR cocktail for his/her patient. Thus, the GMR approach may provide the most effective, yet affordable solution in fighting cancer.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
